2. Search Result
Search Result
Pathways Recommended: PROTAC
Results for "

ALK PROTAC

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

3

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W040304
    Alkynyl Palmitic Acid
    3 Publications Verification

    ALK-C16

    		 PROTAC Linkers Cancer
    Alkynyl Palmitic Acid (Alk-C16) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs . Alkynyl Palmitic Acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Alkynyl Palmitic Acid
  • HY-112155
    MS4078
    4 Publications Verification

    		 PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK .
    MS4078
  • HY-122582
    TL13-12

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    TL13-12 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC50 values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984) .
    TL13-12
  • HY-112156
    MS4077

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37 nM for binding affinity to ALK .
    MS4077
  • HY-123919
    TL13-112
    2 Publications Verification

    		 PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib?(HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .
    TL13-112
  • HY-160506
    PRO-6E

    		PROTACs c-Met/HGFR Apoptosis Cancer
    PRO-6E is an oral active PROTAC based on Cereblon ligand, and induces the degradation of MET with maximum degradation of 81.9% at 1 μM in MKN-45 cells. PRO-6E inhibits tumor growth in vivo and in vitro. PRO-6E induces cell apoptosis and induces cell arrest (Sturcture Note:(Blue: Cereblon ligand (HY-103596), Black: linker；Pink: ALK/c-Met inhibitor Crizotinib (HY-50878)) .
    PRO-6E
  • HY-171825
    SIAIS001

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    SIAIS001 is a CRBN-dependent ALK PROTAC degrader with a DC50 of 3.9 nM. SIAIS001 induces ALK protein degradation via the ubiquitin-proteasome system. SIAIS001 induces G1/S phase cell cycle arrest and inhibits proliferation of cancer cells. SIAIS001 can be used for the research of anaplastic large-cell lymphomas .
    SIAIS001
  • HY-174368
    PROTAC EML4-ALK Degrader-1

    Pro-BA

    		 PROTACs Apoptosis Anaplastic lymphoma kinase (ALK) Cancer
    PROTAC EML4-ALK Degrader-2 (Pro-BA) is a selective and orally active linker-free EML4-ALK PROTAC degrader with the DC50 of 74 nM in H1322 cells (T1/2 = 8 h). PROTAC EML4-ALK Degrader-2 relies on GID4 and proteasome pathways to promote ubiquitination of target proteins, leading to cell apoptosis. PROTAC EML4-ALK Degrader-2 can be used for research on cancer. (Pink: EML4-ALK Ligand (HY-40114); Blue: GID4 Ligand (HY-150908))
    PROTAC EML4-ALK Degrader-1
  • HY-159147
    SIA​​IS039

    		PROTACs ROS Kinase Apoptosis Cancer
    SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC50s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .
    SIA​​IS039
  • HY-147219A
    SIAIS164018 hydrochloride

    		PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis Cancer
    SIAIS164018 hydrochloride is a PROTAC-based ALK and EGFR degrader, with IC50 value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 hydrochloride strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 hydrochloride exhibits better property than Brigatinib (HY-12857) .
    SIAIS164018 hydrochloride
  • HY-W754809
    ALK ligand-1

    		Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) Cancer
    ALK ligand-1 is a ALK ligand that can be used for synthesis of PROTAC ALK degrader-4 (HY-175527) .
    ALK ligand-1
  • HY-147219
    SIAIS164018

    		PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis Cancer
    SIAIS164018 is a PROTAC-based ALK and EGFR degrader, with IC50 value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 exhibits better property than Brigatinib (HY-12857) .
    SIAIS164018
  • HY-161749
    PROTAC ALK degrader-1

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    PROTAC ALK degrader-1 (compound B1) is an ALK degrader based on PROTACs, with the DC50 of 26 nM in H3122 EML4-ALK. PROTAC ALK degrader-1 can be used to synthesis PROTAC ALK degrader-2 (HY-161750) with superior bioavailability .
    PROTAC ALK degrader-1
  • HY-169481
    AP-1

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    AP-1 is a PROTAC targeting anaplastic lymphoma kinase (ALK). AP-1 is composed of PROTAC target protein ligand CS-1243648 (HY-169482) (red part), E3 ligase ligand Pomalidomide (HY-10984) (blue part) and PROTAC Linker 2-(Tert-Butoxy)-2-oxoacetic acid (HY-W687662) (black part) .
    AP-1
  • HY-168551
    PROTAC ALK degrader-3

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    PROTAC ALK degrader-3 (4B) is an orally active ALK degrader based on PROTACs, which can effectively induce persistent degradation of ALK fusion protein in Karpas 299 cells and strong inhibition of downstream pathways,IC50 is 119.33 nM. PROTAC ALK degrader-3 exhibits antitumor activity. (Structure Note: PINK, ALK Inhibitor (HY-15656); Blue, E3 (HY-W023573); Black, linker (HY-168552)) .
    PROTAC ALK degrader-3
  • HY-174315
    WZH-17-002

    		PROTACs Anaplastic lymphoma kinase (ALK) Akt ERK Cancer
    WZH-17-002 is a WZH-15-125-based ALK PROTAC degrader with a DC50 of 25 nM. WZH-17-002 enhances activities against Lorlatinib (HY-12215)-resistant ALK compound mutations. WZH-17-002 significantly reduces drug resistance in ALK-fusion non-small cell lung cancer (NSCLC) and inhibits tumor growth in EML4-ALK G1202R/L1196 M xenograft mice model . Pink: ALK ligand (HY-174314); Blue: CRBN ligase ligand (HY-14658); Black: linker (HY-174316)
    WZH-17-002
  • HY-161750
    PROTAC ALK degrader-2

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    PROTAC ALK degrader-2 (B1-PEG) is an ALK degrader based on PROTACs, with the DC50 of 45 nM in H3122 EML4-ALK DC50 (GSH+). PROTAC ALK degrader-2, through PEGylation, is engineered to self-organize into micelles in water and releases its active form in response to the tumor-specific high GSH environment .
    PROTAC ALK degrader-2
  • HY-174314
    WZH-15-125

    		Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) Cancer
    WZH-15-125 is a potent ALK inhibitor. WZH-15-125 can effectively overcome drug resistance, especially compound ALK mutations. WZH-15-125 has an IC50 of 101.7 nM for the highly refractory G1202R/L1196M mutation that is resistant to Lorlatinib (HY-12215). WZH-15-125 can be used as a PROTAC target protein ligand to synthesize PROTAC WZH-17-002 (HY-174315). WZH-15-125 can be used in the research of non-small cell lung cancer .
    WZH-15-125
  • HY-175527
    ALK degrader 2

    		HyT Anaplastic lymphoma kinase (ALK) Apoptosis Cancer
    ALK degrader 2 is an orally active ALK degrader that degrades EML4-ALK levels (DC50 = 8 nM) and nucleophosmin (NPM)-ALK protein levels (DC50 = 102 nM). ALK degrader 2 mediates ALK degradation via the Hsp70 chaperone system and ubiquitin-proteasome pathway. ALK degrader 2 induces significant S-phase cell cycle arrest and apoptosis in H3122 cells. ALK degrader 2 shows anti-tumor activity in mice bearing H3122 xenografts. ALK degrader 2 can be used for the study of non-small cell lung cancer (NSCLC). (Pink: ALK ligand (HY-W754809), Blue: Hyt (HY-W013021), Black: Linker (HY-Y1760), ALK ligand-linker conjugate (HY-175528)) .
    ALK degrader 2
  • HY-177945
    MS99-β-Gal

    Gal-MS99

    		 PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    MS99-β-Gal (Gal-MS99) is a galactose-modified NPM-ALK PROTAC degrader. MS99-β-Gal is only hydrolyzed by SA-β-gal and esterase in senescent cancer cells, releasing MS99, which specifically degrades the NPM-ALK fusion protein. MS99-β-Gal shows an IC50 of 454.8 nM for aging Karpas 299 cells, significantly lower than that of normal Karpas 299 cells (IC50 = 2.162 μM). MS99-β-Gal can be used for the research of cancer .
    MS99-β-Gal
  • HY-175271
    JWJ-01-378

    		PROTACs Trk Receptor ERK Cancer
    JWJ-01-378 is a selective TRK PROTAC degrader. JWJ-01-378 efficiently degrades WT TRK and TPM3-TRKA fusion proteins and inhibits downstream pERK signaling, while showing limited efficacy against TRK inhibitor resistant mutants and ALK fusions. JWJ-01-378 potently suppresses cancer cell proliferation .Pink: TRK ligand (HY-160520); Blue: CRBN ligase ligand (HY-103596); Black: linker
    JWJ-01-378
  • HY-168552
    3-Hydroxyazetidine-Cyclohexanol

    		PROTAC Linkers Cancer
    3-Hydroxyazetidine-Cyclohexanol is a PROTAC linker that can be used in the synthesis of ALK PROTAC (HY-168551) .
    3-Hydroxyazetidine-Cyclohexanol
  • HY-168553
    3-Hydroxyazetidine-Cyclohexanol-5-Aminothalidomide

    		E3 Ligase Ligand-Linker Conjugates Cancer
    3-Hydroxyazetidine-Cyclohexanol-5-Aminothalidomide is a E3 ligase ligand-linker conjugate that can be used in the synthesis of ALK PROTAC (HY-168551) .
    3-Hydroxyazetidine-Cyclohexanol-5-Aminothalidomide
  • HY-180956
    PROTAC ALK degrader-5

    		PROTACs Anaplastic lymphoma kinase (ALK) STAT Cancer
    PROTAC ALK degrader-5 (Compound 17) is an efficient ALK PROTAC degrader, with its inhibitory effects on EML4-ALK and NPM-ALK being 27.4 nM and 116.5 nM respectively. PROTAC ALK degrader-5 exhibits potent anti-proliferative activity against H3122 and Karpas 299. PROTAC ALK degrader-5 effectively inhibits the phosphorylation of ALK and STAT3. PROTAC ALK degrader-5 can be used for the study of ALK-driven malignant tumors, such as human non-small cell lung cancer and anaplastic large cell lymphoma .
    PROTAC ALK degrader-5
  • HY-179732
    PROTAC ALK degrader-4

    		PROTACs Anaplastic lymphoma kinase (ALK) IGF-1R ERK STAT Cancer
    PROTAC ALK degrader-4 (Compound B8) is an ALK PROTAC degrader with a DC50 of 445.25 nM. PROTAC ALK degrader-4 exhibits excellent anti-proliferative activity against NCI-H2228 and NCI-H3122. PROTAC ALK degrader-4 leads to a significant downregulation of 390 proteins, including IGF-1R and its downstream proteins such as ERK1/2 and STAT3. PROTAC ALK degrader-4 can be used for research on lung adenocarcinoma. (Pink: ALK ligand (HY-15656); Blue: CRBN ligand (HY-179733); Black: linker) .
    PROTAC ALK degrader-4
  • HY-147206D
    Biotin-PEG5000-Alk

    		PROTAC Linkers Cancer
    Biotin-PEG5000-Alk is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Biotin-PEG5000-Alk is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Biotin-PEG5000-Alk
  • HY-169482
    ALK protein ligand-1

    		Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) Cancer
    ALK protein ligand-1 (Compound A1), a ligand for the anaplastic lymphoma kinase (ALK) protein, is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) that exhibits inhibitory effects on ALK. ALK protein ligand-1 can be used in the synthesis of AP-1 (HY-169481) .
    ALK protein ligand-1
  • HY-175528
    ALK ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates Anaplastic lymphoma kinase (ALK) Cancer
    ALK ligand-Linker Conjugate 1 is a ALK ligand-linker conjugate that can be used for synthesis of PROTAC ALK degrader-4 (HY-175527) .
    ALK ligand-Linker Conjugate 1
  • HY-146022
    SIAIS117

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    SIAIS117 is a potent Brigatinib-PROTAC degrader. SIAIS117 is a ALK PROTAC based on Brigatinib and VHL-1 conjunction. SIAIS117 can degrade ALK G1202R point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines. SIAIS117 has the potentially anti-proliferation ability of small cell lung cancer .
    SIAIS117
  • HY-183785
    PROTAC ALK5 Degrader-1

    		PROTACs Anaplastic lymphoma kinase (ALK) Inflammation/Immunology
    PROTAC ALK5 Degrader-1 is a selective ALK5 PROTAC degrader. PROTAC ALK5 Degrader-1 induces ALK5 degradation via ALK5 ATP-binding pocket engagement, CRBN recruitment, and the ubiquitin-proteasome system.PROTAC ALK5 Degrader-1 inhibits ALK5 downstream signaling. PROTAC ALK5 Degrader-1 can be used for the research of pulmonary fibrosis .
    PROTAC ALK5 Degrader-1
  • HY-180972
    PROTAC EML4-ALK Degrader-2

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    PROTAC EML4-ALK Degrader-2 is an EML4-ALK PROTAC degrader. PROTAC EML4-ALK Degrader-2 shows potent selective inhibitory activity to ALK with an IC50 of 1.6 nM. PROTAC EML4-ALK exhibits selectivity over IGF1R, INSR, FLT3, and FGFR2. PROTAC EML4-ALK Degrader-2 shows anti-cancer activities both in vitro and vivo. PROTAC EML4-ALK Degrader-2 can be used for non-small cell lung cancer (NSLC), liver lung and cervical cancer research .
    PROTAC EML4-ALK Degrader-2
  • HY-183441
    ALK5 ligand-1

    		Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) Inflammation/Immunology
    ALK5 ligand-1 (a31's ALK5 ligand) is a ligand of Anaplastic lymphoma kinase ALK5 with higher selectivity for ALK5 than for ALK4. ALK5 ligand-1 can be used to synthesize PROTAC degraders targeting ALK5. ALK5 PROTACs induce ALK5 degradation dependent on the ubiquitin-proteasome system and exert antifibrotic activity. ALK5 ligand-1 can be used in studies of pulmonary fibrosis .
    ALK5 ligand-1
  • HY-183442
    ALK5 ligand-1-amine-C2-piperazine-C4-OH

    		Target Protein Ligand-Linker Conjugates Anaplastic lymphoma kinase (ALK) Inflammation/Immunology
    ALK5 ligand-1-amine-C2-piperazine-C4-OH is a conjugate of a ligand targeting ALK5 and a PROTAC linker. ALK5 ligand-1-amine-C2-piperazine-C4-OH can be used to synthesize the PROTAC degrader (a31). ALK5 PROTACs induce UPS-dependent and selective degradation of ALK5 over ALK4. ALK5 ligand-1-amine-C2-piperazine-C4-OH can be applied to research on pulmonary fibrosis .
    ALK5 ligand-1-amine-C2-piperazine-C4-OH
  • HY-179733
    CRBN ligand-191

    		Ligands for E3 Ligase Cancer
    CRBN ligand-191 is an E3 ligand that can be used for the synthesis of PROTACs, such as PROTAC ALK degrader-4 (HY-179732) .
    CRBN ligand-191
  • HY-183718
    M4K3250

    		PROTACs Anaplastic lymphoma kinase (ALK) Neurological Disease Cancer
    M4K3250 is a selective ALK2 PROTAC degrader with a pDC50 of 7.9. M4K3250 induces the formation of a ternary complex between ALK2 and the E3 ubiquitin ligase CRBN, thereby causing ALK2 degradation and inhibiting ALK2 activity. M4K3250 exhibits cytotoxicity in glioblastoma cells. M4K3250 can be used in studies related to glioblastoma .
    M4K3250
  • HY-180970
    TD-004

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    TD-004 is a potent ALK PROTAC degrader. TD-004 exhibits anti-ALK inhibitory activity with an IC50 of 0.11 µM and selectively inhibits the proliferation of SU-DHL-1 and H3122 cells (ALK-positive cancer cells) with IC50s of 0.058 µM and 0.28 µM, respectively. TD-004 induces degradation of ALK fusion proteins (NPM-ALK and EML4-ALK) via recruitment of the VHL E3 ligase and the proteasome pathway. TD-004 demonstrates significant tumor growth inhibition with a favorable safety profile in vivo. TD-004 can be used for the research of anaplastic large cell lymphoma and non-small cell lung cancer .
    TD-004
  • HY-183717
    M4K3233

    		Cancer
    M4K3233 is a selective ALK2 PROTAC degrader with a pDC50 of 7.3 and a pIC50 of 6.6. M4K3233 recruits CRBN to form a ternary complex with ALK2, mediating ALK2 degradation via the proteasomal and lysosomal pathways. M4K3233 induces moderate downregulation of RIPK2 and significant downregulation of SIK3 in mammalian cells. M4K3233 is applicable to research related to glioblastoma .
    M4K3233
  • HY-180966
    Gly-PEG3-BA

    		PROTACs EGFR Cancer
    Gly-PEG3-BA is an EML4-ALK PROTAC degrader. Gly-PEG3-BA effectively reduces EML4-ALK with a DC50 value of 0.50 μM in H3122 (EML4-ALK) cells. Gly-PEG3-BA effectively reduces EGFR mutant (L858R/T790M) levels with a DC50 of 20.15 μM in H1975 (EGER-L858R/T790M) cells. Gly-PEG3-BA exerts potent antiproliferation activity in H3122 (EML4-ALK) and H1975 (EGER-L858R/T790M) cells with IC50s value of 0.84 and 20.74 μM. Gly-PEG3-BA can be used for non-small lung cancer research .
    Gly-PEG3-BA
  • HY-180965
    Pro-PEG3-BA

    		PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis Cancer
    Pro-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader, degrading EML4 ALK and EGFR mutant (L858R/T790M) with DC 50 values of 0.42 and 13.50 μM, respectively. Pro-PEG3-BA hinders proliferation and induces cell cycle arrest and apoptosis of NSCLC cells in vitro. Pro-PEG3-BA shows safety profile and decreases EML4-ALK protein via rewiring the ubiquitin- proteasome system in vivo. Pro-PEG3-BA can be used for non-small cell lung cancer research .
    Pro-PEG3-BA
  • HY-180964
    Lys-PEG3-BA

    		PROTACs Anaplastic lymphoma kinase (ALK) EGFR Cancer
    Lys-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader with DC50 values of 1.32 and 19.66 μM for H3122 (EML4-ALK) and H1975 (EGFR-L858R/T790M) cells, respectively. Lys-PEG3-BA hinders proliferation via rewiring the ubiquitin- proteasome system in vitro. Lys-PEG3-BA can be used for non-small cell lung cancer research .
    Lys-PEG3-BA
  • HY-183440
    Amine-C2-piperazine-C4-OH

    		PROTAC Linkers Inflammation/Immunology
    Amine-C2-piperazine-C4-OH is a flexible alkyl linker component that can be used in the synthesis of PROTAC ALK5 Degrader-1 (HY-183785). Amine-C2-piperazine-C4-OH can be applied to the research of pulmonary fibrosis .
    Amine-C2-piperazine-C4-OH

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: